| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ligand Pharmaceuticals Inc (LGND) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. LGND is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 161.3K | $35.72M | - | |
| Dir | 44.0K | $9.74M | - | |
| Dir | 33.8K | $7.48M | - | |
| Dir | 32.8K | $7.25M | - | |
| Other | 30.8K | $6.82M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2017 | Korenberg Matthew E | VP, Finance And CFO | Sell | 6,559 | $142.63 | $935,510.17 | -44.6% | |
| Nov 16, 2017 | Kozarich John W61 | Director | Sell | 5,000 | $141.71 | $708,550.00 | -12.3% | |
| Nov 16, 2017 | Higgins John L66 | Chief Executive Officer | Sell | 5,269 | $142.53 | $750,990.57 | -3.5% | |
| Sep 5, 2017 | Higgins John L66 | Chief Executive Officer | Sale+OE | 5,000 | $130.00 | $650,000.00 | -3.5% | |
| Aug 23, 2017 | Aryeh Jason | Director | Sell | 2,000 | $127.99 | $255,980.00 | -1.7% | |
| Aug 9, 2017 | Foehr Matthew W72 | President And COO | Sale+OE | 6,100 | $127.51 | $777,823.81 | -6.0% | |
| Aug 9, 2017 | Berkman Charles S81 | VP, Gen. Counsel &Secretary | Sell | 18,625 | $126.96 | $2,364,670.98 | -43.3% | |
| Aug 8, 2017 | Higgins John L66 | Chief Executive Officer | Sale+OE | 5,483 | $125.00 | $685,375.00 | -3.8% | |
| Jun 9, 2017 | Higgins John L66 | Chief Executive Officer | Sale+OE | 12,000 | $114.87 | $1,378,440.00 | -7.9% | |
| May 12, 2017 | Foehr Matthew W72 | President And COO | Sale+OE | 5,621 | $112.20 | $630,650.34 | -5.7% |